BRAF and juvenile myelomonocytic leukemia: Only a few formal clinical trials have been conducted in pediatric oncology, including trametinib plus dabrafenib (a RAF inhibitor) in glioma with BRAF V600 variants (42), and stand-alone trametinib in refractory juvenile myelomonocytic leukemia (43).